1 2 dioctanoyl sn glycero 3 pa

Antibodies were obtained from the following sources: anti-raptor, -rictor, and -mSIN1 antibodies were from Bethyl Laboratories (Montgomery, TX, USA); MF20 anti-sarcomeric MHC and F5D anti-myogenin antibodies were from the Developmental Studies Hybridoma Bank (developed under the auspices of the National Institute of Child Health and Human Development, National Institutes of Health, and maintained by the Department of Biological Sciences, University of Iowa, Iowa City, IA, USA); anti-DEPTOR were from Novus (Littleton, Colorado, USA). All other primary antibodies were from Cell Signaling Technology (Danvers, MA, USA). All secondary antibodies were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA). 1,2-dioctanoyl-sn-glycero-3–PA was obtained from Avanti Polar Lipids (Alabaster, AL, USA). Akti1/2 were from Calbiochem-Merck (Darmstadt, Germany). Mouse PLD2 shRNA were previously described^{16 (link)}. All other reagents were from Sigma-Aldrich (St. Louis, MO, USA).

Antibodies were obtained from the following sources: FLAG M2 from Sigma-Aldrich (St. Louis, MO); DEPTOR from Novus; tubulin from Abcam (Cambridge, UK); raptor, rictor, and mSin1 from Bethyl laboratory (Montgomery, TX); mTOR from Santa Cruz Biotechnology (Santa Cruz, CA); and all other antibodies from Cell Signaling Technology (Danvers, MA). All secondary antibodies were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA). 1,2-Dioctanoyl-sn-glycero-3–PA was obtained from Avanti Polar Lipids (Alabaster, AL). All other reagents were from Sigma-Aldrich (St. Louis, MO).